Noble Capital analyst Robert LeBoyer initiated coverage of Unicycive Therapeutics with an Outperform rating and $6 price target. Unicycive’s lead drug candidate oxylanthanum carbonate, or OLC, is a phosphate binding agent for the treatment of high phosphate levels in renal dialysis patients that the firm believes will show advantages over the current phosphate binding drugs and has potential to be “the best drug” in a category with over $1B in U.S. sales, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on UNCY:
- Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting
- Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference
- Unicycive Therapeutics issues letter to shareholders
- Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones
- Unicycive Therapeutics enrolls first patient in trial for OLC in CKD